A disadvantage of measuring PD-L1 expression in tumor samples via IHC is that this can only be conducted on a small section of the tumor tissue taken during a single biopsy, disregarding the extensive spatial and temporal heterogeneity of PD-L1 that exists (33). The gene discussed is CD274; the disease is neoplasm.